Filtered By:
Source: Thrombosis Research
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 219 results found since Jan 2013.
P7. Abstract Title: Mapping the Interactome of the Metalloprotease ADAMTS13 in Plasma using In-Vitro BioID
Von Willebrand Factor (VWF) is a multimeric plasma protein that tethers platelets to sites of vascular damage, and is an important initiator of blood clotting. ADAMTS13 is a metalloprotease that cleaves VWF to regulate its platelet binding activity. Decreased activity of ADAMTS13 leads to larger VWF multimers resulting in pathological blood clots, such as thrombotic thrombocytopenic purpura (TTP) and stroke. Unlike other circulating proteases, ADAMTS13 is secreted as an active enzyme and is resistant to all known natural protease inhibitors.
Source: Thrombosis Research - September 30, 2019 Category: Hematology Authors: H. Madarati, C. Kretz Source Type: research
P5. Abstract Title: Characterization of Unfractionated Heparin Infusions in a Comprehensive Stroke Centre
Stroke patients with arterial or venous intraluminal thrombus (ILT) are at high risk of stroke recurrence and embolic or hemorrhagic complications. Treatment with anticoagulation remains challenging in this group of patients due to onset of action, efficacy, and risk of hemorrhage. Traditionally, unfractionated heparin (UFH) has been used due to its short half-life in the context of risk of hemorrhagic transformation of the infarct zone. Heparin nomograms and associated bolus dosing are not standardized in clinical practice across centres and patients can exhibit long epochs of time under or over the therapeutic PTT range.
Source: Thrombosis Research - September 30, 2019 Category: Hematology Authors: H. Khosravani, P. Pham, C. Shen, C. Wong Source Type: research
OC1. Abstract Title: In-hospital Mortality and Morbidity among Patients Presenting with Intracranial Hemorrhage: A Single Center's Experience with Vitamin K Antagonists and the Direct Oral Anticoagulants
Oral anticoagulants are the preferred therapy for the treatment of venous thromboembolism and for stroke prevention among patients with atrial fibrillation. Given their widespread use, clinicians must balance efficacy of anticoagulation with their associated bleeding risks. Specifically, intracranial hemorrhage (ICH) is the most feared complication as this form of bleeding has the highest mortality and morbidity. To date, clinical trials suggest a lower incidence of ICH and better safety profile among patients prescribed the direct oral anticoagulants (DOACs) compared with traditional vitamin k antagonists (VKAs).
Source: Thrombosis Research - September 30, 2019 Category: Hematology Authors: C. Cipkar, S. Srinathan, P. Chiang, L. Castellucci Tags: Oral Communications Source Type: research
Oral anticoagulant-associated bleeding requiring hospitalization in Thai patients: Incidences, risk factors, and outcomes
Oral anticoagulants have been widely used in patients with atrial fibrillation (AF), mechanical valve and in the treatment of both arterial and venous thromboembolism (VTE). Warfarin is the conventional oral anticoagulant which was established its efficacy and safety profiles. Direct oral anticoagulants (DOACs) including dabigatran, rivaroxaban, and apixaban, have gained their popularity and been increasingly used since their approval in Thailand for stroke prevention in AF and VTE treatment.
Source: Thrombosis Research - September 4, 2019 Category: Hematology Authors: Kochawan Boonyawat, Patratorn Kunakorntham, Pantep Angchaisuksiri Tags: Letter to the Editors-in-Chief Source Type: research
Outcomes of direct oral anticoagulant- and warfarin-associated hemorrhage: A single center retrospective cohort study
Direct oral anticoagulants (DOACs) are now a mainstay of anticoagulant therapy for the prevention and treatment of venous thromboembolism (VTE) and stroke prevention in non-valvular atrial fibrillation (a-fib). However, bleeding-related morbidity and mortality remains a feared complication. Bleeding in patients taking DOACs in clinical trials showed comparable, if not more favorable, outcomes compared to that of warfarin [1 –4]. However, the safety of DOAC use should also be evaluated in less selected cohorts in the real-world.
Source: Thrombosis Research - September 2, 2019 Category: Hematology Authors: Lorraine Cafuir, En Cheng, Christine Kempton Tags: Letter to the Editors-in-Chief Source Type: research
Prospective study of plasma high molecular weight kininogen and prekallikrein and incidence of coronary heart disease, ischemic stroke and heart failure
High molecular weight kininogen (HK) and prekallikrein (PK) are proteins in the kallikrein/kinin system of the coagulation cascade. They play an important role in the contact activation system of the intrinsic coagulation pathway, renin-angiotensin activation, and inflammation. Hence these proteins have been posited to affect the occurrence of cardiovascular events and thus to be potential therapeutic targets. Previous case-control studies have provided inconsistent evidence for an association of HK and PK with cardiovascular disease.
Source: Thrombosis Research - August 21, 2019 Category: Hematology Authors: Romil R. Parikh, Aaron R. Folsom, Jeffrey R. Misialek, Wayne D. Rosamond, Patricia P. Chang, Weihong Tang, Mary Cushman Tags: Full Length Article Source Type: research
Fluorescent activity-based probe for the selective detection of Factor VII activating protease (FSAP) in human plasma
The zymogen form of circulating Factor VII activating protease (FSAP) is activated by histones that are released as a consequence of tissue damage or excessive inflammation. This is likely to have consequences in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer. To investigate the existence, as well as the concentration, of active FSAP (FSAPa) in complex biological systems an active site probe is needed. We used Hybrid Combinatorial Substrate Library (HyCoSuL) to screen for natural and unnatural amino acids that specifically bind to P4-P2 pockets of FSAPa.
Source: Thrombosis Research - August 18, 2019 Category: Hematology Authors: Wioletta Rut, Nis Valentin Nielsen, Justyna Czarna, Marcin Poreba, Sandip M. Kanse, Marcin Drag Tags: Full Length Article Source Type: research
Recurrent venous thromboembolism after cerebral venous thrombosis: which lower-risk survivors are at risk for recurrence?
When speaking to young, high-functioning survivors of cerebral venous thrombosis (CVT) and other causes of stroke in the young, one common theme that emerges in follow-up is fear of recurrence. CVT is known to have an excellent functional prognosis in most, with 85 –90% achieving functional independence with the ability to carry out all previous activities [1,2]. However, as a rare cause of stroke in the young, an already rare event, CVT can be a traumatic and isolating experience, compounded by the aggravations of anticoagulation, and made worse by residual “invisible” deficits such as headache, fatigue, and neurops...
Source: Thrombosis Research - May 30, 2019 Category: Hematology Authors: Thalia S. Field Tags: Editorial Source Type: research
Anticoagulation and antiplatelet therapy in stable coronary artery disease: A multicenter survey
Oral anticoagulation (OAC) is superior to antiplatelet therapy to prevent stroke in patients with atrial fibrillation (AF). In contrast, patients who have experienced an acute coronary event and/or coronary stent placement benefit from antiplatelet therapy to prevent future adverse cardiac events. While both of these cardiac conditions are highly prevalent on their own, they also frequently occur concurrently. In these situations, combined antiplatelet therapy and OAC significantly increases the risk of bleeding events [1,2].
Source: Thrombosis Research - May 26, 2019 Category: Hematology Authors: David Kopin, W. Schuyler Jones, Andrew Klein, Geoffrey D. Barnes Tags: Letter to the Editors-in-Chief Source Type: research
Non-invasive imaging techniques for the differentiation of acute and chronic thrombosis
Thrombosis is the localized clotting of blood that can occur in both the arterial and venous circulation. It is a key factor in the pathogenesis of acute coronary syndrome, myocardial infarction and stroke and the primary cause of deep vein thrombosis and pulmonary embolism. Rapid and accurate diagnosis of thrombotic episodes is crucial in reducing the morbidity and potential mortality associated with arterial and venous thrombotic disorders by allowing early targeted therapeutic interventions. From a clinical perspective the ability to accurately assess the age and composition of thrombus is highly desirable given that an...
Source: Thrombosis Research - March 13, 2019 Category: Hematology Authors: Nur Nazifah Mohd Yusof, Andrew McCann, Peter J. Little, Hang T. Ta Tags: Review Article Source Type: research
The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis
Factor (F) Xa inhibitors are safe and effective alternatives to warfarin in the treatment of venous thrombosis and as stroke prophylaxis in patients with non-valvular atrial fibrillation. Even though the risk of major bleeding is lower for FXa inhibitors than warfarin in general, FXa inhibitors have been reported to cause a different bleeding profile. Inhibition of FXa by rivaroxaban is associated with more gastrointestinal bleeds and heavy uterine bleedings [1 –3] than warfarin. Also, low-dose rivaroxaban has been shown to reduce major ischemic outcomes and death after acute coronary events [4].
Source: Thrombosis Research - March 12, 2019 Category: Hematology Authors: Nina Haagenrud Schultz, P ål Andre Holme, Carola Elisabeth Henriksson, Marie-Christine Mowinckel, Per Morten Sandset, Vibeke Bratseth, Eva-Marie Jacobsen Tags: Letter to the Editors-in-Chief Source Type: research
Association between fibrinogen and fibrinogen γ’ and atherosclerotic plaque morphology and composition in symptomatic carotid artery stenosis: Plaque-At-RISK study
Von Willebrand Factor (VWF), ADAMTS13, fibrinogen and fibrinogen γ’ are associated with an increased risk of ischemic stroke. Carotid atherosclerosis is an important risk factor for ischemic stroke. Characteristics of the vulnerable plaque; intraplaque hemorrhage (IPH), plaque ulceration and lipid-rich necrotic core (LRNC) can be visualized with imaging techni ques. Since atherosclerosis might attribute to the association between coagulation factors and ischemic stroke risk, the aim of this study is to investigate the association between coagulation factors and atherosclerotic plaque characteristics in more detail.
Source: Thrombosis Research - February 27, 2019 Category: Hematology Authors: A.C. van Dijk, S.J. Donkel, T. Zadi, M.A.H. Sonneveld, F.H.B.M. Schreuder, M.F. Chohan, P.J. Koudstaal, F.W.G. Leebeek, R. Saxena, J. Hendrikse, M.E. Kooi, A. van der Lugt, M.P.M. de Maat Tags: Full Length Article Source Type: research
Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide
Anticoagulant therapy is commonly prescribed for both the acute treatment, and long-term prevention of venous thromboembolism (VTE), and as primary and secondary prevention of stroke in the context of atrial fibrillation (AF) [1]. Until recently the majority of patients requiring chronic anticoagulant therapy were prescribed vitamin K antagonists (VKA), as these were the only oral anticoagulant agents available [1]. A requirement for regular monitoring and VKA-drug or-food interactions has meant that not all patients that have an indication for anticoagulation have benefitted from these agents.
Source: Thrombosis Research - February 12, 2019 Category: Hematology Authors: Jon Mabley, Jignesh P. Patel, Abdelrahman Sayed, Roopen Arya, Greg Scutt Tags: Letter to the Editors-in-Chief Source Type: research
Association of platelet-derived microvesicles and their phenotypes with carotid atherosclerosis and recurrent vascular events in patients after ischemic stroke
Platelet-derived microvesicles (pMVs) exhibit procoagulant and proinflammatory properties and play a role in the development and progression of atherosclerosis. The study examined the association between the total number of pMVs and their phenotypes with carotid atherosclerosis and recurrent vascular events (VEs) in patients in the convalescent phase of ischemic stroke (IS).
Source: Thrombosis Research - February 2, 2019 Category: Hematology Authors: Justyna Rosi ńska, Wojciech Ambrosius, Joanna Maciejewska, Robert Narożny, Wojciech Kozubski, Maria Łukasik Tags: Full Length Article Source Type: research
Bugs in the system
Bugs play a large role in our life. Bugs can be either good, or bad for us. Microorganisms, such as gut microbiota, are usually beneficial to us. They provide a barrier to pathogenic organisms and help to digest our food. However, microbiota also produce Trimethylamine-N-oxide (TMAO), a metabolite of dietary phosphatidylcholine and L-carnitine, that has been recently been shown to increase the risk of arterial thrombotic events, such as myocardial infarction and stroke. In this issue of Thrombosis Research, Reiner and colleagues have investigated whether plasma levels of TMAO also associate with recurrent venous thromboemb...
Source: Thrombosis Research - January 30, 2019 Category: Hematology Authors: Henri H. Versteeg, Marc Rodger Source Type: research
